Mallinckrodt inks deal to acquire Sucampo Pharmaceuticals

26 December 2017

In its third M&D deal this year, UK-incorporated Mallinckrodt (NYSE: MNK) has signed an agreement to acquire US biopharma company Sucampo Pharmaceuticals (Nasdaq: SCMP), including its commercial and development assets, sending the latter’s shares up 5.44% to $17.92 in early market trading today.

The transaction, valuing Sucampo at around $1.2 billion, or $840 million, excluding debt, was approved by the boards of directors of both companies. Mallinckrodt will commence a cash tender offer for $18.00 per share, which is 5.9% above last Friday’s close, with support from key Sucampo shareholders. The transaction is expected to close in first-quarter 2018.

Shares surged as much as 18% early this month, after Sucampo confirmed it is reviewing options including a sale of the business after receiving takeover interest, according to people familiar with the matter, giving the Rockville, Maryland-based company a then market value of $760 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK